Clinical trials: Advanced Malignant Cancer, open to volunteers
Advanced Malignant Tumors
A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors
This is a single-arm, open-label, single-center, dose-escalation platform clinical trial design. Using an adenovirus vector platform, the study aims to evaluate the safety, tolerability, pharmacokinetic characteristics, and…
- Trial name
- NCT07409766
- Testing
- CAR-M
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Soft Tissue Sarcoma Adult, Angiosarcoma
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma.
- Conditions
- Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- PROPANE (NCT05961761)
- Testing
- Propranolol, Pembrolizumab
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 80 people
- Sponsor
- Niels Junker
Advanced Malignant Neoplasm
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.
- Trial name
- NCT06394713
- Testing
- QLF31907, Irinotecan, Docetaxel
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Advanced Malignant Tumor
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in…
- Trial name
- NCT06823609
- Testing
- QLS1304 tablet
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Tumors
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
- Trial name
- NCT07205198
- Testing
- SIBP-A10
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Institute Of Biological Products
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Advanced Malignant Solid Tumours
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT06888830
- Testing
- JS212 for Injection
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Malignant Female Reproductive System Neoplasm
Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients
This clinical trial studies whether physiatry-led cancer prehabilitation can be used during systemic treatment before surgery (neoadjuvant systemic treatment [NST]) to improve function in stage III-IVA gynecologic cancer…
- Trial name
- NCT07608445
- Testing
- Educational Intervention, Goal Setting, Interview
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer, Breast Cancer
Myeloprotection With Trilaciclib in Pan-cancer Population
The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT06297811
- Testing
- Trilaciclib Injection, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Bone Metastases in Subjects With Advanced Cancer
SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue
This is a randomized, controlled, prospective phase II, two-arm clinical study designed to evaluate the efficacy and safety of using either Spatially Fractionated Radiotherapy (SFRT) or Stereotactic Central Ablative Radiotherapy…
- Trial name
- NCT06987370
- Testing
- Conventional Radiotherapy (CRT), SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong Cancer Hospital and Institute
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Malignant Neoplasm
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
- Trial name
- NCT07600749
- Testing
- MK-4884
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Mesothelioma, Malignant
SW-682 in Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway…
- Trial name
- NCT06251310
- Testing
- SW-682, Combination Therapy
- Where
- 8 sites in United States
- Volunteers
- 186 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Malignancies
Phase I Study of XZ120 in Malignant Tumors
This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast…
- Trial name
- NCT06206915
- Testing
- XZ120 injection
- Volunteers
- 123 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Advanced/Metastatic Solid Tumors
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy…
- Trial name
- NCT07102004
- Testing
- MHB088C for Injection
- Where
- China
- Volunteers
- 515 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
CLDN18.2 Positive Solid Tumors
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
- Trial name
- NCT07680257
- Testing
- SUV2208A cell injection, SUV2208A
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Celest Therapeutics (Shanghai) Co., Ltd.